Seminars in Perinatology
Volume 34, Issue 2 , Pages 134-144 , April 2010

History and Current Status of Newborn Screening for Hemoglobinopathies

  • Jane M. Benson, BA

      Affiliations

    • Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Bradford L. Therrell Jr, MS, PhD

      Affiliations

    • Department of Pediatrics, University of Texas Health Science Center at San Antonio, National Newborn Screening and Genetics Resource Center, Austin, TX
    • Corresponding Author InformationAddress reprint requests to Bradford L. Therrell Jr, MS, PhD, National Newborn Screening and Genetics Resource Center, 1912 W. Anderson Lane 210, Austin, TX 78757

References 

  1. Chernoff AI, Fisher B, Harris JW, et al. A system of nomenclature for the varieties of human hemoglobin. Science. 1953;118:116–117
  2. Giardine B, van Baal S, Kaimakis P, et al. HbVar database of human hemoglobin variants and thalassemia mutations: 2007 Update. Hum Mutat. 2007;28:206-206
  3. Newborn screening. Toward a uniform screening panel and system. Genet Med. 2006;8(suppl 1):1S–252S
  4. Embury SH. Alpha thalassemia (A modifier of sickle cell disease). Ann NY Acad Sci. 1989;565:213–221
  5. Thein SL. Genetic modifiers of the beta-haemoglobinopathies. Br J Haematol. 2008;141:357–366
  6. Embury SH, Clark MR, Monroy G, et al. Concurrent sickle cell anemia and alpha-thalassemia (Effect on pathological properties of sickle erythrocytes). J Clin Invest. 1984;73:116–123
  7. Gibbons R, Higgs DR, Olivieri NF, et al. The alpha thalassemias and their interaction with structural haemoglobin variants. In:  Weatherall DJ,  Clegg JB editor. The Thalassemia Syndromes. Malden, MA: Blackwell, Science, Inc; 2001;p. 484–525
  8. In:  Noguchi L,  Schechter AN,  Rodgers GP,  Higgs DR,  Weatherall DJ editor. Bailliere's Clinical Hematology: The Hemoglobinopathies (6). London: Bailliere Tindall; 1993;p. 57–91
  9. Bookchin RM, Nagel RL, Ranney HM. Structure and properties of hemoglobin C-Harlem, a human hemoglobin variant with amino acid substitutions in 2 residues of the beta-polypeptide chain. J Biol Chem. 1967;242:248–255
  10. Moo-Penn WF, Schmidt RM, Jue DL, et al. Hemoglobin S Travis: a sickling hemoglobin with two amino acid substitutions [beta6(A3)glutamic acid leads to valine and beta142 (h20) alanine leads to valine). Eur J Biochem. 1977;77:561–566
  11. Moo-Penn W, Bechtel K, Jue D, et al. The presence of hemoglobin S and C Harlem in an individual in the United States. Blood. 1975;46:363–367
  12. Aksoy M. The hemoglobin E syndromes (II. Sickle-cell-hemoglobin E disease). Blood. 1960;15:610–613
  13. Singer K, Singer L, Goldberg SR. Studies on abnormal hemoglobins (XI. Sickle cell-thalassemia disease in the Negro; the significance of the S + A + F and S + A patterns obtained by hemoglobin analysis). Blood. 1955;10:405–415
  14. Vichinsky E. Hemoglobin E Syndromes. Hematology. 2007;79–83
  15. Thein SL. Pathophysiology of {beta} thalassemia—A Guide to molecular therapies. Hematology. 2005;31–37
  16. Brittenham G, Schechter A, Noguchi C. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood. 1985;65:183–189
  17. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med. 2001;74:179–184
  18. Itano HA, Pauling L. A rapid diagnostic test for sickle cell anemia. Blood. 1949;4:66–68
  19. Pauling L, Itano HA. Sickle cell anemia, a molecular disease. Science. 1949;109:443
  20. Nalbandian RM, Nichols BM, Camp FR, et al. Automated dithionite test for rapid, inexpensive detection of hemoglobin S and non-S sickling hemoglobinopathies. Clin Chem. 1971;17:1033–1037
  21. Murayama M. Structure of sickle cell hemoglobin and molecular mechanism of the sickling phenomenon. Clin Chem. 1967;13:578–588
  22. Nalbandian RM, Henry RL, Nichols BM, et al. Molecular basis for a simple, specific test for S hemoglobin: the Murayama test. Clin Chem. 1970;16:945–950
  23. Schmidt RM, Wilson SM. Standardization in detection of abnormal hemoglobins (Solubility tests for hemoglobin S). JAMA. 1973;225:1225–1230
  24. Smithies O. Zone electrophoresis in starch gels: Group variations in the serum proteins of normal human adults. Biochem J. 1955;61:629–641
  25. Kohn J. Separation of haemoglobins on cellulose acetate. J Clin Pathol. 1969;22:109–111
  26. Schneider RG. Electrophoretic methods in hemoglobin identifications. Hemoglobin. 1980;4:521–526
  27. Clegg JB, Naughton MA, Weatherall DJ. An improved method for the characterization of human haemoglobin mutants: identification of alpha-2-beta-2-95GLU, haemoglobin N (Baltimore). Nature. 1965;207:945–947
  28. Drysdale JW, Righetti P, Bunn HF. The separation of human and animal hemoglobins by isoelectric focusing in polyacrylamide gel. Biochim Biophys Acta. 1971;229:42–50
  29. Vesterberg O. Isoelectric focusing of proteins in polyacrylamide gels. Biochim Biophys Acta. 1972;257:11–19
  30. Huntsman RG, Metters JS, Yawson GI. The diagnosis of sickle cell disease in the newborn infant. J Pediatr. 1972;80:279–281
  31. Garrick MD, Dembure P, Guthrie R. Sickle-cell anemia and other hemoglobinopathies (Procedures and strategy for screening employing spots of blood on filter paper as specimens). N Engl J Med. 1973;288:1265–1268
  32. New York Public Health Laws 2500, in McKinney's Session Laws of New York, Chap 943, pp 1490 (1974)
  33. New York Public Health Laws 2500, in McKinney's Session Laws of New York, Chap 1015, sect 1, pp 1624 (1974)
  34. Pass KA, Gauvreau AC, Schedlbauer L, et al. Newborn screening for sickle cell disease. In:  Carter TP,  Wiley AM editor. Genetic Disease Screening and Management. New York, NY: Alan R. Liss; 1986;p. 359–372
  35. Black J. Isoelectric focusing in agarose gel for detection and identification of hemoglobin variants. Hemoglobin. 1984;8:117–127
  36. Hempe JM, Granger JN, Craver RD. Capillary isoelectric focusing of hemoglobin variants in the pediatric clinical laboratory. Electrophoresis. 1997;18:1785–1795
  37. Lorey F, Cunningham G, Shafer F, et al. Universal screening for hemoglobinopathies using high-performance liquid chromatography: clinical results of 2 (2 Million screens). Eur J Hum Genet. 1994;2:262–271
  38. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer. 2009;52:486–490
  39. Diggs LW, Flowers E. Sickle cell anemia in the home environment (Observations on the natural history of the disease in Tennessee children). Clin Pediatr. 1971;10:697–700
  40. Neel JV. The inheritance of sickle cell anemia. Science. 1949;110:64–66
  41. Beet EA. The genetics of sickle cell trait in a Bantu tribe. Ann Eugen. 1949;14:279–284
  42. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180:326–328
  43. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–343
  44. Perutz MF. The hemoglobin molecule. Sci Am. 1964;211:64–76
  45. Scott RB. Health care priority and sickle cell anemia. JAMA. 1970;214:731–734
  46. Scott RB. Sickle-cell anemia—High prevalence and low priority. N Engl J Med. 1970;282:164–165
  47. Scott RB. A commentary on sickle cell disease. J Natl Med Assoc. 1971;63:1–2passim
  48. Reid C, Rodgers G. Sickle cell disease: Demystifying the beginnings. In:  Pace BS editors. Renaissance of Sickle Cell Disease Research in the Genomic Era. London, Great Britain: World Scientific; 2007;p. 1–12
  49. Schmidt RM. Hemoglobinopathy screening: approaches to diagnosis, education and counseling. Am J Public Health. 1974;64:799–804
  50. Schmidt RM, Brosious EM. Basic Laboratory Methods of Hemoglobinopathy Detection. Atlanta, GA: DHEW; 1972;Vol. Publ: No. (CDC) 76-8266
  51. Schmidt RM, Moo-Penn WF, Brosious EM. Advanced Laboratory Methods of Hemoglobinopathy Detection. Atlanta, GA: DHEW; 1974;Vol. Publ. Numbers 75-8296
  52. Schmidt RM, Brosious EM. Evaluation of proficiency in the performance of tests for abnormal hemoglobins. Am J Clin Pathol. 1974;62:664–669
  53. deJesus VR, Mei JV, Bell CJ, et al: Improving and assuring newborn screening laboratory quality worldwide: thirty-year experience at the Centers for Disease Control and Prevention. Semin Perinatol (in press)
  54. Wilson SM, Schmidt RM. Evaluation of a solubility test kit and an automated machine for detecting hemoglobin S. Clin Chem. 1974;20:1138–1140
  55. Schmidt RM, Brosious EM, Holland S. Quantitation of fetal hemoglobin by densitometry. J Lab Clin Med. 1974;84:740–745
  56. Schmidt RM, Holland S. Standardization in abnormal hemoglobin detection (An evaluation of hemoglobin electrophoresis kits). Clin Chem. 1974;20:591–594
  57. Brosious EM, Morrison BY, Schmidt RM. Effects of hemoglobin F levels, KCN, and storage on the isopropanol precipitation test for unstable hemoglobins. Am J Clin Pathol. 1976;66:878–882
  58. Brosious EM, Wright JM, Baine RM, et al. Microchromatographic methods for hemoglobin A2 quantitation compared. Clin Chem. 1978;24:2196–2199
  59. Brosious EM, Schmidt RM. Quantitation of hemoglobin F (An interlaboratory study). Am J Clin Pathol. 1979;72:421–425
  60. Schmidt RM. Laboratory diagnosis of hemoglobinopathies. JAMA. 1973;224:1276–1280
  61. Schmidt RM, Rucknagel DL, Necheles TF. Comparison of methodologies for thalassemia screening by Hb A2 quantitation. J Lab Clin Med. 1975;86:873–882
  62. Schmidt RM, Brosious EM, Holland S, et al. Use of blood specimens collected on filter paper in screening for abnormal hemoglobins. Clin Chem. 1976;22:685–687
  63. Baine RM, Brown HG. Evaluation of a commercial kit for microchromatographic quantitation of hemoglobin A2 in the presence of hemoglobin S. Clin Chem. 1981;27:1244–1247
  64. Huisman TH, Schroeder WA, Brodie AN, et al. Microchromatography of hemoglobins (II. A simplified procedure for the determination of hemoglobin A2). J Lab Clin Med. 1975;86:700–702
  65. Singer K, Chernoff AI, Singer L. Studies on abnormal hemoglobins (II. Their identification by means of the method of fractional denaturation). Blood. 1951;6:429–435
  66. Betke K, Marti HR, Schlicht I. Estimation of small percentages of foetal haemoglobin. Nature. 1959;184(suppl 24):1877–1878
  67. Carrell RW, Kay R. A simple method for the detection of unstable haemoglobins. Br J Haematol. 1972;23:615–619
  68. Dacie JV, Grimes AJ, Meisler A, et al. Hereditary Heinz-body anaemia (A report of studies on five patients with mild anaemia). Br J Haematol. 1964;10:388–402
  69. Grimes AJ, Meisler A, Dacie JV. Congenital Heinz-body anaemia (Further evidence on the cause of Heinz-body production in red cells). Br J Haematol. 1964;10:281–290
  70. Rigas DA, Koler RD. Decreased erythrocyte survival in hemoglobin H disease as a result of the abnormal properties of hemoglobin H: the benefit of splenectomy. Blood. 1961;18:1–17
  71. Koepke JA, Thoma JF, Schmidt RM. Identification of human hemoglobins by use of isoelectric focusing in gel. Clin Chem. 1975;21:1953–1955
  72. Baiget M, Gomez Pereira C, Jue DL, et al. A case of hemoglobin Indianapolis [beta 112(G14) Cys–Arg] in an individual from Cordoba, Spain. Hemoglobin. 1986;10:483–494
  73. Ballas SK, Park D, Fernandez L, et al. Erythrocytosis secondary to HB Bunbury [alpha 2 beta (2)94(FG1)Asp–Asn]. Hemoglobin. 1992;16:281–286
  74. Bonaventura J, Bonaventura C, Sullivan B, et al. Hemoglobin Providence (Functional consequences of two alterations of the 2,3-diphosphoglycerate binding site at position beta 82). J Biol Chem. 1976;251:7563–7571
  75. Bonaventura C, Arumugam M, Cashon R, et al. Chloride masks effects of opposing positive charges in Hb A and Hb Hinsdale (beta 139 Asn—>Lys) that can modulate cooperativity as well as oxygen affinity. J Mol Biol. 1994;239:561–568
  76. McDonald MJ, Michalski LA, Turci SM, et al. Structural, functional, and subunit assembly properties of hemoglobin Attleboro [alpha 138 (H21) Ser–Pro], a variant possessing a site maturation at a critical C-terminal residue. Biochemistry. 1990;29:173–178
  77. Moo-Penn WF, Bechtel KC, Schmidt RM, et al. Hemoglobin Raleigh (beta1 valine replaced by acetylalanine) (Structural and functional characterization). Biochemistry. 1977;16:4872–4879
  78. Moo-Penn WF, McPhedran P, Bobrow S, et al. Hemoglobin Connecticut (beta 21 (B3) Asp leads to Gly): a hemoglobin variant with low oxygen affinity. Am J Hematol. 1981;11:137–145
  79. Moo-Penn WF, Jue DL, Johnson MH, et al. Structural and functional studies of hemoglobin Wayne: an elongated alpha-chain variant. J Mol Biol. 1984;180:1119–1140
  80. Turner GJ, Galacteros F, Doyle ML, et al. Mutagenic dissection of hemoglobin cooperativity: effects of amino acid alteration on subunit assembly of oxy and deoxy tetramers. Proteins. 1992;14:333–350
  81. Winslow RM. Laboratory Methods for Detecting Hemoglobinopathies. Atlanta: Department of Health and Human Services (Centers for Disease Control and Prevention); 1984;
  82. Schmidt RM, Brosious EM, Wright JM. Preparation and use of a quality control hemolysate for microchromatographic determinations of hemoglobin A2. Am J Clin Pathol. 1977;67:215–218
  83. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol/Oncol. 1982;4:197–201
  84. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia (A randomized trial). N Engl J Med. 1986;314:1593–1599
  85. Consensus conference (Newborn screening for sickle cell disease and other hemoglobinopathies). JAMA. 1987;258:1205–1209
  86. Lloyd-Puryear MA, Therrell BL, Mann MY, et al. The role of the federal government in supporting newborn screening programs. In:  Baily MA,  Murray TH editor. Ethics in Newborn Screening: New Technologies, New Challenges. Baltimore, MD: Johns Hopkins University Press; 2009;p. 178–194
  87. Therrell BL, Johnson A, Williams D. Status of NBS programs in the United States. In:  Schmidt BJ,  Diament AJ,  Loghin-Grosso NS editor. Current Trends in Infant Screening. Amsterdam: Elsevier Science; 1988;p. 331–337
  88. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease (Rates and risk factors). N Engl J Med. 1991;325:11–16
  89. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis (The cooperative study of sickle cell disease). Pediatrics. 1999;103:640–645
  90. Smith LA, Oyeku SO, Homer C, et al. Sickle cell disease: a question of equity and quality. Pediatrics. 2006;117:1763–1770
  91. Kan YW, Golbus MS, Trecartin R. Prenatal diagnosis of sickle-cell anemia. N Engl J Med. 1976;294:1039–1040
  92. Kan YW, Dozy AM. Antenatal diagnosis of sickle-cell anaemia by DNA analysis of amniotic-fluid cells. Lancet. 1978;2:910–912
  93. Kan YW, Dozy AM. Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. Proc Natl Acad Sci U S A. 1978;75:5631–5635
  94. Chang JC, Kan YW. Antenatal diagnosis of sickle cell anaemia by direct analysis of the sickle mutation. Lancet. 1981;2:1127–1129
  95. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350–1354
  96. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol. 1986;51:263–273
  97. Wong C, Dowling CE, Saiki RK, et al. Characterization of beta-thalassaemia mutations using direct genomic sequencing of amplified single copy DNA. Nature. 1987;330:384–386
  98. McCabe ER, Huang SZ, Seltzer WK, et al. DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. Hum Genet. 1987;75:213–216
  99. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487–491
  100. Saiki RK, Chang CA, Levenson CH, et al. Diagnosis of sickle cell anemia and beta-thalassemia with enzymatically amplified DNA and nonradioactive allele-specific oligonucleotide probes. N Engl J Med. 1988;319:537–541
  101. Jinks DC, Minter M, Tarver DA, et al. Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet. 1989;81:363–366
  102. McCabe ER, Zhang YH, Descartes M, et al. Rapid detection of beta s DNA from Guthrie cards by chromogenic probes. Lancet. 1989;2:741
  103. Descartes M, Huang Y, Zhang YH, et al. Genotypic confirmation from the original dried blood specimens in a neonatal hemoglobinopathy screening program. Pediatr Res. 1992;31:217–221
  104. Zhang YH, McCabe ER. Analysis from newborn screening dried blood specimens. Hum Genet. 1992;89:311–314
  105. Sylvester-Jackson DA, Page SL, White JM, et al. Unbiased analysis of the frequency of beta-thalassemia point mutations in a population of African-American newborns. Arch Pathol Lab Med. 1993;117:1110–1114
  106. Zhang YH, McCabe LL, Wilborn M, et al. Application of molecular genetics in public health: improved follow-up in a neonatal hemoglobinopathy screening program. Biochem Med Metab Biol. 1994;52:27–35
  107. Bhardwaj U, Zhang YH, McCabe ER. Neonatal hemoglobinopathy screening: molecular genetic technologies. Mol Genet Metab. 2003;80:129–137
  108. Sutcharitchan P, Embury SH. Advances in molecular diagnosis of inherited hemoglobin disorders. Curr Opin Hematol. 1996;3:131–138
  109. Dunbar S. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta. 2006;363:71–82
  110. Strom C, Janeszco R, Quan F, et al. Technical validation of a TM biosciences Luminex-based multiplex assay for detecting the American College of Medical Genetics recommended cystic fibrosis mutation panel. J Mol Diagn. 2006;8:371–375
  111. Aslanian S, Azimi M, Noble J, et al. Application of flow cytometry-based genotyping for rapid detection of hemoglobin variants. Int J Lab Hematol. 2007;29:284–291
  112. Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110:908–912
  113. Vrettou C, Traeger-Synodinos J, Tzetis M, et al. Rapid screening of multiple {beta}-globin gene mutations by real-time PCR on the LightCycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. Clin Chem. 2003;49:769–776
  114. Steinberg K, Gallagher M. Methods for assessing genotypes in human genome epidemiology studies. In:  Khoury MJ,  Little J,  Burke W editor. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York, NY: Oxford University Press; 2003;p. 79–91
  115. Creary LE, Ulug P, Menzel S, et al. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One. 2009;4:e4218
  116. Menzel S, Thein SL. Genetic architecture of hemoglobin F control. Curr Opin Hematol. 2009;16:179–186
  117. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129:465–481
  118. Steinberg M. Genetic etiologies for phenotypic diversity in sickle cell anemia. ScientificWorldJournal. 2009;9:46–67
  119. Sebastiani P, Timofeev N, Dworkis D, et al. Genome-wide association studies and the genetic dissection of complex traits. Am J Hematol. 2009;84:504–515
  120. Howell RR, Lloyd-Puryear M: From developing guidelines to implementing legislation: actions of the U.S. Advisory Committee on Heritable Disorders in newborns and children towards advancing and improving newborn screening. Semin Perinatol (in press)
  121. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia (Prophylactic penicillin study II). J Pediatr. 1995;127:685–690
  122. Kolnagou A, Kontoghiorghes G. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease (Experience from a Cyprus model and its use as a paradigm for future applications). Hemoglobin. 2009;33:287–295
  123. Ault P, Jones K. Understanding iron overload: Screening, monitoring, and caring for patients with transfusion-dependent anemias. Clin J Oncol Nurs. 2009;13:511–517
  124. Austin H, Lally C, Benson JM, et al. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009;200:e1–e3
  125. Schnedl WJ, Krause R, Halwachs-Baumann G, et al. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care. 2000;23:339–344
  126. Wiwanitkit V. Problem of using hemoglobin A1C measurement in endemic area of hemoglobinopathy. Prim Care Diabetes. 2007;1:173–175
  127. Schnedl WJ, Trinker M, Lipp RW. HbA1c determination in patients with hemoglobinopathies. Diabetes Care. 1999;22:368–369
  128. Miller R, Segal J, Ashar B, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006;81:236–241
  129. Kark JA, Posey DM, Schumacher HR, et al. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med. 1987;317:781–787
  130. Tsaras G, Owusu-Ansah A, Boateng F, et al. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009;122:507–512
  131. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704–712

 Supported in part by HRSA grant U32MC00148.

 The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, the Health Resources and Services Administration, the US Department of Health and Human Services, or the University of Texas Health Science Center at San Antonio.

PII: S0146-0005(09)00111-6

doi: 10.1053/j.semperi.2009.12.006

Seminars in Perinatology
Volume 34, Issue 2 , Pages 134-144 , April 2010

Article Tools